The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Shares surge on massive volume after EPS Ventures announced its intention to acquire LNG shipping firm Cool Company.
A flurry of multi-billion dollar acquisitions by Pfizer, Genmab, and Axcelis signals renewed confidence and strategic positioning in high-growth sectors.
Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.
The deal paves the way for the integration of Monogram's advanced surgical robotics, with a closing date set for early October 2025.
Gaming giant to be acquired by a private equity consortium including Silver Lake and Saudi Arabia's PIF at a 25% premium, sending shares higher.